Vera Therapeutics Inc - Class A

NASDAQ: VERA
$48.31
+$1.28 (+2.7%)
Closing Price on November 22, 2024

VERA Stock Chart and Intraday Price

VERA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 2,639.17M USD
Shares Outstanding 53,707,000
Vera Therapeutics Inc, based in Brisbane, California, is a biotechnology firm dedicated to creating innovative treatments for severe immunological diseases. With a focus on research and development, its flagship product, atacicept, is a pioneering fusion protein aimed at treating immunoglobulin A nephropathy and lupus nephritis through subcutaneous injections in advanced clinical trials. Additionally, Vera is working on MAU868, a monoclonal antibody designed to combat BK viremia infections, showcasing its commitment to addressing unmet medical needs in immunology.

VERA Articles

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published: